Asymmetric dimethylarginine (ADMA) and cardiovascular disease

Vascular Disease Prevention

Volumn 3, Issue 4, 2006, Pages 291-295

  Ueda, Seiji ^a   Yamagishi, Sho Ichi ^a   Kaneyuki, Utako ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Atherosclerosis; Chronic kidney disease; Dimethylarginine; Nitric oxide; Oxidative stress

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

EID: 33750697587     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567270000603010041     Document Type: Review

References (73)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
2. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular disease. Circulation 1997: 96: 379-82.
3. Cooke JP. Dose ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7.
4. Harrison DG. Cellular and molecular mechanisms of endotherial cell dysfunction. J Clin Invest 1997; 100: 2153-7.
5. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
6. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6.
7. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary event and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-8.
8. Tarnow L, Hovind P, Teerlink T, et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-9.
9. Zoccali C, Bode-Böger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-7.
10. G-dimethylarginine by human endothelial cells. Endothelium 1993; 1: 137-40.
11. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105.
12. Rawal N, Rajpurohit R, Paik WK, et al. Purification and characterization of S-adenosylmethionine-protein-arginine N-methyltransferase from rat liver. Biochem J 1994; 300: 483-9.
13. Ghosh SK, Paik WK, Kim S. Purification and molecular identification of two protein methylase I from calf brain: myelin basic protein-and histone-specific enzyme. J Biol Chem 1988; 263: 19024-33.
14. Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucl Acid Res Mol Biol 1998; 61: 65-131.
15. Osnai T, Saitoh M, Sasaki S, et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42: 985-90.
16. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
17. G-dimethyl-arginine, N-mono-, di-, and trimethyllysine, and glucosylgalactosyl-, and galactosyl-d-hydroxylysine from human urine. J Biol Chem 1970; 245: 5751-8.
18. G-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-84.
19. Kielstein JT, Boger RH, Bode-Böger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-6.
20. Fliser D, Kielstein JT, Haller H, et al. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int 2003; 84: S37-40.
21. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148: 671-7.
22. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
23. MacAllister RJ, Fickling SA, Whitley GS, et al. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112: 43-8.
24. G-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem Tokyo 1995; 117: 237-8.
25. G-dimethylarginine dimethylaminohydrolase. Eur J Biochem 1998; 258: 863-8.
26. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 1999; 1343: 209-14.
27. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-40.
28. Ueda S, Kato S, Matsuoka H, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226-33.
29. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
30. Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension 1995; 25: 1202-11.
31. Arnal J-F, Michel J-B, Harrison DG. Nitric oxide in the pathogenesis of hypertension. Curr Opin Nephrol Hypertens 1995; 4: 182-8.
32. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
33. MacAllister RJ, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol 1994; 5: 1057-65
34. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, Una, and vasoactive hormones in healthy humans. Am J Physiol 1996; 270: F845-51.
35. Ruilope LM, Lahera VK Rodicio JL, et al. Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens 1994; 12: 625-31.
36. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-7.
37. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108: 3042-7.
38. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5.
39. Markus C, Tasao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75.
40. Schulman IH, Zhou MS, Raij L. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Curr Hypertens Rep 2005; 7: 61-7.
41. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
42. Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
43. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-81.
44. Ito A, Egashira K, Narishige T, et al. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001; 65: 775-8.
45. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
46. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
47. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-5.
48. Xiong Y, Fu YF, Fu SH, et al. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 2003; 42:191-6.
49. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287:1420-6.
50. Paiva H, Lehtimaki T, Laakso J, et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52: 303-7.
51. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 2005; 45: 525-32.
52. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferatoractivated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 717-26.
53. Dobrian AD, Schriver SD, Khraibi AA, et al. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004; 43: 48-56.
54. Achan V, Tran CT, Arrigoni F, et al. All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90: 764-9.
55. Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in Rats. Hypertens Res 2005; 28: 255-62.
56. Boger RH, Bode-Boger SM, Sydow K, et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20: 1557-64.
57. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
58. Tsubouchi H, Inoguchi T, Sonta T, et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005; 39: 444-52.
59. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
60. Jiang JL, Jiang DJ, Tang YH, et al. Effect of simvastatin on endothelium-dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004 ; 25: 893-901.
61. Paiva H, Laakso J, Lehtimaki T, et al. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003; 41: 219-22.
62. Lu TM, Ding YA, Leu HB, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 157-61.
63. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-30.
64. Feng Q, Lu X, Fortin AJ, et al. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 1998; 37: 667-75.
65. Saitoh M, Osanai T, Kamada T, et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 2003; 18: 177-82.
66. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339-45.
67. Harris P. Congestive cardiac failure: central role of the arterial blood pressure. Br Heart J 1987; 58: 190-203.
68. Chen Y, Li Y, Zhang P, et al. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol 2005; 289: H2212-9.
69. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 1999; 10: 1053-8.
70. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-7.
71. Cross J, Donald A, Vallance P, et al. Dialysis improves endothelial function in humans. Nephrol Dial Transplant 2001; 16: 1823-9.
72. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-61.
73. Ravani P, Tripepu G, Mallberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-55.